Novo Nordisk's CagriSema is making headlines after new data showed big weight loss and changes in how the brain reacts to food. Here is a simple explainer.

What is it: CagriSema combines two drugs, cagrilintide and semaglutide, that work together on appetite and metabolism. It is being developed as an obesity treatment.

What the new study found: In a 52-week trial presented at EASD 2026 in Milan, patients lost an average of 22.4 percent of body weight. Brain scans showed reduced responses to high-calorie food cues, and patients reported less food noise, fewer cravings and less hunger.

Why it matters: Obesity affects hundreds of millions of people, and existing drugs already sell in huge volumes. A drug that works on the brain's food signals could help patients who struggle with constant hunger.

What next: The drug still needs larger trials and regulatory approval before it can reach patients. Doctors caution that lifestyle changes remain the foundation of weight management.